4 Results for "

FAP2286

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "FAP2286" in MCE Product Catalog:

  • Targets Recommended:
7
7 Cited Publications
Cat. No.: HY-147057
CAS No.: 2581741-18-4
Purity:  99.54%
Synonyms: FAP-2286
Target:  

FAP

Research Areas:  

Cancer

Rofapitide tetraxetan (FAP-2286) is a potent and selective FAP-binding peptide with a mean IC50 value of 2.7 nM for binding to FAP. Rofapitide tetraxetan can be labeled with radionuclides for diagnostic applications. Rofapitide tetraxetan has antitumor activity .
loading...
    loading...
Cat. No.: HY-147057A
Synonyms: FAP-2286 acetate
Target:  

FAP

Research Areas:  

Cancer

Rofapitide tetraxetan (FAP-2286) acetate is a potent and selective FAP-binding peptide with a mean IC50 value of 2.7 nM for binding to FAP. Rofapitide tetraxetan acetate can be labeled with radionuclides for diagnostic applications. Rofapitide tetraxetan acetate has antitumor activity .
loading...
    loading...
Cat. No.: HY-173374
CAS No.: 3114056-16-2
Target:  

FAP Drug Derivative

Research Areas:  

Cancer

DOTAGA-FAP-2286-ALB is a derivative of Rofapitide tetraxetan (HY-147057). DOTAGA-FAP-2286-ALB is a selective fibroblast activation protein (FAP) inhibitor with an IC50 value of 67.5 nM. DOTAGA-FAP-2286-ALB enhances tumor retention via albumin interaction, prolonging blood circulation and improving radiometal complex stability (e.g., with 111In and 225Ac). DOTAGA-FAP-2286-ALB is promising for research of radionuclide therapy (TRT) of FAP-positive solid tumors .
loading...
    loading...
Cat. No.: HY-P11602
CAS No.: 3107530-08-2
Target:  

FAP

Research Areas:  

Cancer

DOTA-C1-FAP-2286 is a cysteic acid-modified fibroblast activation protein (FAP)-targeting radioligand. DOTA-C1-FAP-2286 binds competitively to FAP with an IC50 of 127.64 nM. DOTA-C1-FAP-2286 is targeted accumulation in FAP-expressing cells and exhibits accelerated renal clearance. DOTA-C1-FAP-2286 can be used as a PET/CT tracer in cancer .
loading...
    loading...